Home › Research › Tau biomarkers
Mosaic Loss of Chromosome Y and Plasma Aβ42/p‐tau181 Ratio as Biomarkers for Alzheimer's Disease in the Midwestern Amish
Yeunjoo E. Song, Ping Wang, Reneé A. Laux, Sarada L. Fuzzell, Sherri D. Hochstetler, Kristy L. S. Miskimen, Audrey H. Lynn, Weihuan Wang et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Background In aging men, mosaic loss of chromosome Y (mLOY) is a possible biomarker for increased risk of disease, including Alzheimer disease (AD). We previously reported mLOY increased with age and carriers of mLOY had an increased risk of AD. We also found plasma Aβ42/p‐tau181 ratio (APR) was significantly lower among AD Amish individuals compared to cognitively‐unimpaired (CU) individuals. We now examine how these two biomarkers interplay with cognitive status in Amish males. Method mLOY was determined using the Mosaic Chromosomal Alterations(MoChA) pipeline. Extensive QC was done for both mLOY and plasma biomarker measures. Consensus review of medical history and neuropsychological testing categorized individuals into AD, Mild‐cognitive‐impairment (MCI) or Cognitive‐impairment‐not‐AD (CINAD) or CU. The cognitively‐impaired (CI) group combined AD, MCI and CINAD. We compared 1) CI to CU and 2) AD to CU. Correlation between APR and mLOY were estimated accounting for relatedness. Receiver operating characteristic analysis was performed to evaluate the discriminatory ability of the two biomarkers compared to the baseline model with age and presence/absence of APOE ε4 alleles. p ‐value <0.05 was noted as statistically significant. Result 249 males (mean age=82.89±5.57) had measurements for both biomarkers. Of these, a subset had consensus diagnoses AD ( n = 30; mean age=85.63±5.31), CINAD, MCI or CU ( n = 105; mean age=82.01±5.36). The mean age of 82 CI individuals was 84.34±4.73. mLOY was observed in 20.1% of CU vs. 29.3% of CI ( p ‐value=0.23). APR was significantly negatively correlated with CI and AD as expected, was positively correlated with mLOY but not significantly and remained positively correlated when stratified, with the stronger correlation in AD. For AD, the area under the curve (AUC) improved from 0.70 to 0.82 with the inclusion of APR, with mLOY showing little effect. For CI, AUC improved from 0.63 to 0.68 by including mLOY, with no independent effect of APR. When including both in the model, AUC improves from 0.63 to 0.69. Conclusion We observed two promising biomarkers of AD, mLOY and APR, both contribute discriminating AD and CI but differently. This and the stringer correlation in AD may indicate they are more specific to AD than non‐specific CI.
What this study adds
Evidence grade: Low
The record lists 30 participants. This study examined mosaic loss of chromosome Y and the plasma Aβ42/p-tau181 ratio as possible biomarkers for Alzheimer's disease in Amish men. Reported effect size: 20.1%; 29.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Song, Y. E., Wang, P., Laux, R. A., Fuzzell, S. L., Hochstetler, S. D., Miskimen, K. L. S., et al. (2025). Mosaic Loss of Chromosome Y and Plasma Aβ42/p‐tau181 Ratio as Biomarkers for Alzheimer's Disease in the Midwestern Amish. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_106620
Vancouver
Song YE, Wang P, Laux RA, Fuzzell SL, Hochstetler SD, Miskimen KLS, et al. Mosaic Loss of Chromosome Y and Plasma Aβ42/p‐tau181 Ratio as Biomarkers for Alzheimer's Disease in the Midwestern Amish. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_106620.
BibTeX
@article{song2025-dff7ac55,
author = {Song, Yeunjoo E. and Wang, Ping and Laux, Reneé A. and Fuzzell, Sarada L. and Hochstetler, Sherri D. and Miskimen, Kristy L. S. and Lynn, Audrey H. and Wang, Weihuan and others},
title = {{Mosaic Loss of Chromosome Y and Plasma Aβ42/p‐tau181 Ratio as Biomarkers for Alzheimer's Disease in the Midwestern Amish}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_106620},
url = {https://doi.org/10.1002/alz70856_106620}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Abstract Background In aging men, mosaic loss of chromosome Y (mLOY) is a possible biomarker for increased risk of disease, including Alzheimer disease (AD).
- We previously reported mLOY increased with age and carriers of mLOY had an increased risk of AD.
- We also found plasma Aβ42/p‐tau181 ratio (APR) was significantly lower among AD Amish individuals compared to cognitively‐unimpaired (CU) individuals.
- Receiver operating characteristic analysis was performed to evaluate the discriminatory ability of the two biomarkers compared to the baseline model with age and presence/absence of APOE ε4 alleles. p ‐value <0.05 was noted as statistically significant.
- Result 249 males (mean age=82.89±5.57) had measurements for both biomarkers.
Why it matters
This study examined mosaic loss of chromosome Y and the plasma Aβ42/p-tau181 ratio as possible biomarkers for Alzheimer's disease in Amish men. It is a biomarker study and does not test or demonstrate any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants30
- Effect size20.1%; 29.3%
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 30 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Jonathan L. Haines: h-index 127 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Case Western Reserve University: institution h-index 1,159 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.